Shanghai MicroPort CardioFlow Medtech
CompanyChina
Shanghai MicroPort CardioFlow Medtech develops 2 assets, the furthest in human trials (Microport CardioFlow Transcatheter Mitral Valve Replacement System in degenerative mitral regurgitation). Mostly device; based in China.
- 2
- Assets
- Furthest stage
- Human trials
- 1
- Trial
- 1
- Signal
Pipeline
2Microport CardioFlow Transcatheter Mitral Valve Replacement System
Transcatheter replacement device for degenerative mitral valve regurgitation
Human trials, Device, degenerative mitral regurgitation
Transcatheter aortic valve system for replacement of diseased aortic valves.
Human trials, Device, aortic valve stenosis
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Trials1
- Signals1